Crossmark

Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting

Crossref DOI link: https://doi.org/10.1007/s00415-024-12853-9

Published Online: 2024-12-21

Published Print: 2025-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zilioli, A.

Rosenberg, A.

Mohanty, R.

Matton, A.

Granberg, T.

Hagman, G.

Lötjönen, J.

Kivipelto, M.

Westman, E. https://orcid.org/0000-0002-3115-2977
Funding

Funding for this research was provided by:

Karolinska Institute
License Information

Text and Data Mining valid from 2024-12-21

Version of Record valid from 2024-12-21
More Information

Article History

Received: 21 August 2024

Revised: 2 December 2024

Accepted: 3 December 2024

First Online: 21 December 2024

Declarations

:

: AZ, AR, RM, AM, GH, TG, EW declare no conflicts of interest. MK serves on the scientific advisory boards for Combinostics. JL is a shareholder at Combinostics.

: The Karolinska University Hospital electronic database and biobank for clinical research (GEDOC) and this study have received ethical approval (Regional Ethical Review Board in Sweden). All procedures were performed with the participants’ informed consent.

Document is current

Any future updates will be listed below